NasdaqGS:ZVRAPharmaceuticals
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data
In early August 2026, Zevra Therapeutics reported Q2 2026 results showing higher sales of US$39.66 million alongside lower net income of US$8.75 million compared with the prior year, while also highlighting strong US uptake of its Niemann-Pick disease type C therapy MIPLYFFA (arimoclomol).
A separate publication of four-year, real-world data on arimoclomol in a broad Niemann-Pick disease type C population, including adults, adds clinically rich evidence that extends beyond prior pivotal...